Trials / Completed

CompletedNCT00729651

Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263)

A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women

Status: Completed
Phase: Phase 4
Study type: Interventional
Enrollment: 343 (actual)

Sponsor: Organon and Co · Industry
Sex: Female
Age: 18 Years
Healthy volunteers: Not accepted

Summary

To demonstrate the efficacy/safety of Fosamax Plus D

Conditions

Osteoporosis Postmenopausal

Interventions

Type	Name	Description
DRUG	alendronate sodium (+) cholecalciferol	Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
DRUG	Comparator: Alendronate sodium (Fosamax)	Alendronate sodium; tablet, once weekly, for 16 weeks
DIETARY_SUPPLEMENT	Comparator: Calcium	500 mg oral tablet calcium once daily, for 16 weeks

Timeline

Start date: 2008-03-20
Primary completion: 2009-04-10
Completion: 2009-04-10
First posted: 2008-08-07
Last updated: 2024-04-23
Results posted: 2010-04-02

Source: ClinicalTrials.gov record NCT00729651. Inclusion in this directory is not an endorsement.